FDA issues warning letter to Daytrana manufacturer

Share this article:

Noven Pharmaceuticals, which manufactures Shire's attention deficit hyperactivity disorder patch Daytrana said it received a warning letter from the FDA related to a prior on-site inspection of its manufacturing facility in Miami.

In the warning letter, the FDA requests additional information and analysis related to deficiencies associated with the peel force specifications for removal the Daytrana system's release liner.

The requests that Noven to take prompt action to address the FDA's concerns, stating failure to do so may result in further regulatory action.

Noven said in a statement it is 'working very closely' with to 'promptly' respond to the FDA letter, and is committed to working collaboratively with regulators to fully resolve the issues.

Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.